GHK-Cu common uses, half-life, side effects and more

GHK-Cu is a copper complex of a short peptide the body makes on its own. Skin creams and serums list it as Copper Tripeptide-1 and it is a common cosmetic ingredient. People also inject it as a gray-market peptide for skin, hair, and recovery. The injected form has never been given to a person in any published study. The compound was developed as a wound drug in the 1990s and failed a 511-patient trial. It reached the market instead as a wound dressing cleared on the path used for bandages.

• Skin serums for fine lines, texture, and firmness
• Scalp products and injections aimed at thicker hair
• Wound and post-procedure skin recovery
• Injected gray-market use for general anti-aging

Topical products are applied once or twice daily. Injected community use is usually daily for blocks of several weeks.

Skin products are sold at 1% to 2% GHK-Cu and a few compounded creams reach 3% to 4%. Injected community use runs 1 to 2 mg under the skin daily. That injected figure comes from packaging rather than from any study. A 50 mg vial mixed with 3 mL of water puts 1.67 mg at the 10-unit mark on an insulin syringe. Users push back on each other at 5 mg and above where injection pain and copper worries start. The human trials used far less than the shop shelf. The negative leg-ulcer trial used a 0.4% cream. Label percentages also cannot be compared across brands. The raw ingredient ships at either 0.1% or 1% actual peptide and no brand states which one it used.

• Injection pain usually starts hours after the shot rather than during it and a painless injection is not a sign it was tolerated
• Keep vitamin C and strong acids in a separate application because low pH breaks the copper complex apart
• Niacinamide, hyaluronic acid, and ceramides layer with it without trouble
• A dose drawn from a 50/10/10 blend vial delivers a full standalone GHK-Cu amount rather than a token one

No human pharmacokinetic study of GHK-Cu exists by any route. Rat work found the injected peptide breaks apart in blood within minutes into a two amino acid fragment that clears quickly. The copper it carried stays behind and joins the body's ordinary copper pool.

GHK-Cu powder and solution are blue to blue-violet from the copper. Loss of that color suggests the complex has broken down. A white or colorless product is a sign it is not GHK-Cu. Protect it from light, heat, and chelators such as EDTA.

• Injection-site pain that begins hours after the shot and can last into the next day
• Welts, lumps, and bruising at injection sites that sometimes persist for weeks
• Skin breakouts around the second week of injecting
• Stinging or redness from topical products
• Full-body hives in one account after a month of daily injections

GHK is a three amino acid peptide that binds copper tightly and carries it into cells. Copper is a required part of two enzymes that cross-link collagen and elastin and defend cells against oxidation. Skin and wound cell studies report effects on fibroblasts, matrix turnover, and inflammatory signaling. The peptide also shifts the balance between the enzymes that break skin matrix down and the proteins that block them. A widely quoted claim that GHK changes more than 4,000 genes comes from a database query run against two cancer cell lines. It counted how many gene probes moved by half or more at a single dose. The authors of that analysis wrote that gene profiling data cannot yet be translated into biological effects.

GHK-Cu was tested properly as a drug and did not pass. A 511-patient trial in diabetic foot ulcers missed its endpoint in 1994. It returned to market as a wound dressing rather than as a medicine. That failed trial was never published and the smaller positive one before it is still what consumer articles cite. An independent trial in 86 patients found the cream no better than placebo. A blinded facial study after laser resurfacing found no objective difference and only patient satisfaction improved. The modern review literature is essentially one author's and he founded two companies selling it. His early biochemistry is real and appeared in strong journals. The claim that blood GHK falls with age traces to his unpublished 1973 thesis. No human study of injected GHK-Cu exists.

• Each 2 mg injection delivers about 315 micrograms of copper and that is roughly a full day of what a hospital gives through a drip
• The 10 mg daily copper limit assumes the gut throttles absorption and a needle bypasses that defense entirely
• Wilson disease and liver disease are the main copper risks and most people who have either do not know it yet
• A routine blood copper test does not show whether copper is building up in the body
• FDA named the injectable route specifically for immunogenicity risk from aggregation and peptide impurities
• Pregnancy, breastfeeding, and use in children have no safety data for either route